Bionest attended BIO Europe in Munich last month and witnessed firsthand the flurry of deal making activity. In many ways 2015 has been a landmark year for deal making. Companies big and small have made headlines, striking deals across every corner of the industry and for myriad reasons ranging from combination collaborations to the recent...
The recent news of Jimmy Carter’s excellent response to cancer immunotherapy — he reported earlier this week that his brain cancer appears to be gone following treatment with Keytruda — was highlighted this morning on the Today Show. The field of immunotherapy – an approach that leverages the body’s own immune system to treat disease...
We were pleased to participate in a “State of the Industry” panel on immuno-oncology at the 2015 BIO Investor Forum in October. The lively discussion included other participants from across the industry and investing world, including the licensing office of Merck & Co. and Baxter’s corporate venture arm, Baxalta, as well as small biotech company...